tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Cidara Therapeutics (CDTX)
NASDAQ:CDTX
US Market
CDTX
Cidara Therapeutics
RESEARCH TOOLSreports
Advertisement

Cidara Therapeutics (CDTX) Stock News & Sentiment

Compare
829 Followers
Cidara Therapeutics’ CD388 Study: A Potential Game-Changer in Influenza Prevention
Premium
Company Announcements
Cidara Therapeutics’ CD388 Study: A Potential Game-Changer in Influenza Prevention
3d ago
CDTX
Promising Phase 2b Results for Cidara’s CD388 Justify Buy Rating Amidst Strong Preventive Efficacy Against Influenza
Premium
Ratings
Promising Phase 2b Results for Cidara’s CD388 Justify Buy Rating Amidst Strong Preventive Efficacy Against Influenza
10d ago
CDTX
Buy Rating for Cidara Therapeutics: Promising Antiviral CD388 Targets $5 Billion Influenza Market
Premium
Ratings
Buy Rating for Cidara Therapeutics: Promising Antiviral CD388 Targets $5 Billion Influenza Market
15d ago
CDTX
Cidara Therapeutics: Strategic Advancements and Financial Strength Bolster Buy Rating
Premium
Ratings
Cidara Therapeutics: Strategic Advancements and Financial Strength Bolster Buy Rating
22d ago
CDTX
Cidara Therapeutics: Strong Buy Rating Backed by Breakthrough Therapy Designation and Promising CD388 Efficacy
Premium
Ratings
Cidara Therapeutics: Strong Buy Rating Backed by Breakthrough Therapy Designation and Promising CD388 Efficacy
22d ago
CDTX
Cidara Therapeutics Expands Phase 3 Trial for CD388
Premium
Company Announcements
Cidara Therapeutics Expands Phase 3 Trial for CD388
1M ago
8K
CDTX
Cidara Therapeutics’ Accelerated Path to BLA Approval and Expanded Market Potential Boosts Buy Rating
Premium
Ratings
Cidara Therapeutics’ Accelerated Path to BLA Approval and Expanded Market Potential Boosts Buy Rating
1M ago
CDTX
More CDTX News >

CDTX News on the Web

Why Cidara Therapeutics, Inc.’s (CDTX) Stock Is Up 5.08%
AAII
Neutral
Why Cidara Therapeutics, Inc.’s (CDTX) Stock Is Up 8.29%
AAII
Neutral
H.C. Wainwright reiterates Cidara as top pick after influenza data
The Fly
Neutral
Cidara Therapeutics Sets Spotlight on Phase 2 CD388 Data at ID Week 2025—Fast Track Status and Universal Influenza Prevention Drive Attention
Market Chameleon
Neutral
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza
Zacks
Bullish
FDA Grants Breakthrough Therapy Status to CD388: Cidara Advances Novel Influenza Prevention for High-Risk Adults
Market Chameleon
Neutral
Why Cidara Therapeutics, Inc.’s (CDTX) Stock Is Up 5.04%
AAII
Neutral
Cidara Therapeutics Secures Up to $339M BARDA Award for Universal Influenza Preventative CD388
Market Chameleon
Neutral

News Score - Last 7 Days

Neutral
CDTX
Sector Average
Media Buzz
This Week2 articles
Weekly Average1.75 articles
News Sentiment
This Week50%
Sector Average56%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is CDTX’s Media Buzz Sentiment?
2 articles about CDTX were published this week. In an average week, 1.75 articles are published.
    What is CDTX’s weekly average amount of articles?
    In an average week, 1.75 articles about CDTX are published.
      What is CDTX’s News Sentiment?
      50% of articles about CDTX were positive this week, compared to its sector average of 56%.
        Healthcare Stocks that are Trending in the News
        RNAAvidity Biosciences
        AVTRAvantor
        HCAHCA Healthcare
        SLPSimulations Plus
        BBIOBridgeBio Pharma
        Showing the stocks with the most bullish news sentiment over the past week

        Become an Expert with TipRanks Premium

        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis
        Subscribe NowSee Plans & Pricing